{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T13:27:01Z","timestamp":1691501221070},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T00:00:00Z","timestamp":1673740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T00:00:00Z","timestamp":1673740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["1R38AI140297","K08 CA237726-01A1"],"award-info":[{"award-number":["1R38AI140297","K08 CA237726-01A1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1245\/s10434-023-13101-6","type":"journal-article","created":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T00:02:28Z","timestamp":1673740948000},"page":"2586-2589","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["National Trends in Management of Pathologic Stage III Melanoma"],"prefix":"10.1245","volume":"30","author":[{"given":"Kristen E.","family":"Rhodin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma E.","family":"Farrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,15]]},"reference":[{"issue":"6","key":"13101_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(16)00141-8.","journal-title":"Lancet Oncol"},{"issue":"23","key":"13101_CR2","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in Melanoma. N Engl J Med. 2017;376(23):2211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1613210.","journal-title":"N Engl J Med"},{"issue":"5","key":"13101_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(15)70122-1.","journal-title":"Lancet Oncol"},{"issue":"19","key":"13101_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med"},{"issue":"3","key":"13101_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683\u201390. https:\/\/doi.org\/10.1245\/s10434-007-9747-3.","journal-title":"Ann Surg Oncol"},{"key":"13101_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005370","author":"KK Broman","year":"2022","unstructured":"Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, et al. International center-level variation in utilization of completion lymph node dissection and adjuvant systemic therapy for sentinel lymph node positive melanoma at major referral centers. Ann Surg. 2022. https:\/\/doi.org\/10.1097\/SLA.0000000000005370.","journal-title":"Ann. Surg."},{"issue":"12","key":"13101_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","volume":"104","author":"ZS Morris","year":"2011","unstructured":"Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104(12):510\u201320. https:\/\/doi.org\/10.1258\/jrsm.2011.110180.","journal-title":"J R Soc Med"},{"key":"13101_CR8","doi-asserted-by":"crossref","unstructured":"Patel S. LBA6 - Neoadjuvant versus adjuvant pembrolizumab for resected stage III\u2013IV melanoma (SWOG S1801). Presented at the ESMO Congress, 11 Sep 2022: Paris.","DOI":"10.1016\/j.annonc.2022.08.039"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13101-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T14:06:30Z","timestamp":1681135590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13101-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,15]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["13101"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13101-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,15]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Georgia Beasley has received clinical trial funding paid to Duke University from Delcath, Istari, Replimune, Oncosec, and Checkmate, and has served on a one-time advisory board for Cardinal Health and Regeneron. She is also supported by NIH K08 CA237726-01A1. Kristen E. Rhodin is supported by NIH 1R38AI140297. Norma E. Farrow, Maria Xu, Jay Lee, and Douglas S. Tyler have no disclosures to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}